Cargando…

CAR-T Cell–Mediated B-Cell Depletion in Central Nervous System Autoimmunity

BACKGROUND AND OBJECTIVES: Anti-CD20 monoclonal antibody (mAb) B-cell depletion is a remarkably successful multiple sclerosis (MS) treatment. Chimeric antigen receptor (CAR)-T cells, which target antigens in a non-major histocompatibility complex (MHC)–restricted manner, can penetrate tissues more t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Sasha, Simic, Milos, Sagan, Sharon A., Shepherd, Chanelle, Duecker, Jason, Sobel, Raymond A., Dandekar, Ravi, Wu, Gregory F., Wu, Wesley, Pak, John E., Hauser, Stephen L., Lim, Wendell, Wilson, Michael R., Zamvil, Scott S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853314/ https://www.ncbi.nlm.nih.gov/pubmed/36657993 http://dx.doi.org/10.1212/NXI.0000000000200080

Ejemplares similares

B‐cell very late antigen‐4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity
por: Lehmann‐Horn, Klaus, et al.
Publicado: (2015)

Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity
por: Schulze-Topphoff, Ulf, et al.
Publicado: (2012)

Can Systemic Anti-CD20 B Cell-Depleting Antibodies Eliminate Meningeal Follicles in Multiple Sclerosis?
por: Gupta, Sasha, et al.
Publicado: (2021)

T cell deletional tolerance restricts AQP4 but not MOG CNS autoimmunity
por: Sagan, Sharon A., et al.
Publicado: (2023)

Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning
por: Daniels, Kyle G., et al.
Publicado: (2022)

CNS accumulation of regulatory B cells is VLA-4-dependent
por: Lehmann-Horn, Klaus, et al.
Publicado: (2016)

Anti-CD20 therapy depletes activated myelin-specific CD8(+) T cells in multiple sclerosis
por: Sabatino, Joseph J., et al.
Publicado: (2019)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
por: Sagan, Sharon A., et al.
Publicado: (2017)

Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity
por: Schulze-Topphoff, Ulf, et al.
Publicado: (2013)

Mitigating alemtuzumab-associated autoimmunity in MS: A “whack-a-mole” B-cell depletion strategy
por: Meltzer, Ethan, et al.
Publicado: (2020)

CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse
por: Vu, Khoan, et al.
Publicado: (2022)

Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory
por: Viaud, Sophie, et al.
Publicado: (2018)

Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies
por: Zhang, Chaoting, et al.
Publicado: (2020)

Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion
por: Wang, Ting, et al.
Publicado: (2022)

Neither T-helper type 2 nor Foxp3(+) regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity
por: Weber, Martin S, et al.
Publicado: (2014)

Repetitive Pertussis Toxin Promotes Development of Regulatory T Cells and Prevents Central Nervous System Autoimmune Disease
por: Weber, Martin S., et al.
Publicado: (2010)

Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy
por: Das, Shipra, et al.
Publicado: (2023)

Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma
por: Wu, Jiaying, et al.
Publicado: (2021)

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome
por: Pfeiffer, Anett, et al.
Publicado: (2018)

Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model
por: Singh, Aman P., et al.
Publicado: (2019)

CAR T cells for treating autoimmune diseases
por: Blache, Ulrich, et al.
Publicado: (2023)

B cell depletion in autoimmune disease
por: Gorman, Claire, et al.
Publicado: (2003)

Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus
por: Rive, Craig M., et al.
Publicado: (2022)

CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?
por: Velasco, Roser, et al.
Publicado: (2023)

CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes
por: Lacan, Claire, et al.
Publicado: (2023)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

Universal CARs, universal T cells, and universal CAR T cells
por: Zhao, Juanjuan, et al.
Publicado: (2018)

Lactate Dehydrogenase A Depletion Alters MyC-CaP Tumor Metabolism, Microenvironment, and CAR T Cell Therapy
por: Mane, Mayuresh M., et al.
Publicado: (2020)

CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy
por: Rodriguez-Garcia, Alba, et al.
Publicado: (2021)

New development in CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2017)

CAR-T cells and CAR-Tregs targeting conventional type-1 dendritic cell suppress experimental autoimmune encephalomyelitis
por: Moorman, Cody D., et al.
Publicado: (2023)

Demyelination, and remyelination by Schwann cells and oligodendrocytes after kainate-induced neuronal depletion in the central nervous system
por: Dusart, I., et al.
Publicado: (1992)

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
por: Su, Lihe, et al.
Publicado: (2022)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Depletion of Specific Cell Populations by Complement Depletion
por: Dittel, Bonnie N.
Publicado: (2010)

IMMU-14. SynNotch chimeric antigen receptor (CAR) T-cells as a potential treatment for diffuse intrinsic pontine glioma (DIPG)/diffuse midline glioma (DMG)
por: Ferrerosa, Lauren, et al.
Publicado: (2022)

Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma
por: Zhang, Huanxin, et al.
Publicado: (2022)

CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro
por: Liu, Maoxuan, et al.
Publicado: (2022)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jojp6k257uql8u1c3n55i495k4